Ajay Virmani, MD
Interventional Cardiology · Winchester, VANPI 1871559773
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AstraZeneca at 54.8% of the total. Reporting peaked in 2021 at $5,527 and has fallen 66.5% since, to $1,852 in 2025.
Across 193 payments — averaging $98.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Boston Scientific$2K
- Philips North America LLC$2K
- Siemens Medical Solutions USA, Inc.$1K
- Johnson & Johnson$753
- Medtronic$727
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$9,70051%
- Travel & lodging$2,97016%
- Food & beverage$6,14732%
- Education$1761%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $10,412 |
| Boston Scientific | 16 | $2,026 |
| Philips North America LLC | 16 | $1,648 |
| Siemens Medical Solutions USA, Inc. | 2 | $1,307 |
| Johnson & Johnson | 50 | $753 |
| Medtronic(2 entities) | 22 | $727 |
| Amgen | 7 | $309 |
| Abiomed | 7 | $299 |
| Actelion Pharmaceuticals US, Inc. | 2 | $225 |
| Esperion Therapeutics, Inc. | 2 | $201 |
| Edwards Lifesciences | 1 | $170 |
| Pfizer | 4 | $143 |
| Novartis | 5 | $107 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $97 |
| Merck | 1 | $85 |
| Abbott | 4 | $81 |
| Boehringer Ingelheim | 4 | $73 |
| Bayer | 1 | $72 |
| Tactile Systems Technology Inc | 3 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $45 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Stryker | 1 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Novo Nordisk | 2 | $31 |
| Terumo Medical Corporation | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$9,950
- Artis icono floor$1,262
- Artis pheno$1,262
- WATCHMAN Access System$1,156
- (9520) IGT Devices Undivided$597
- Azurion 7 B20$485
- XARELTO$374
- Repatha$245
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$170
- GENERAL - THERAPIES$169
- (5028) IGT Devices Systems Undivided$137
- Micra$135
- UPTRAVI$125
- OPSUMIT$125
- NEXLIZET$125
- NEXLETOL$125
- VYNDAQEL$123
- LOKELMA$106
- GENERAL - STRUCTURAL HEART$105
- (6577) Visions 014$104
How this compares
$18,994 in reported general payments places this provider in the 80th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 451 | $507,391 |
| MounjaroTirzepatide | 409 | $491,374 |
| EntrestoSacubitril/Valsartan | 342 | $477,524 |
| EliquisApixaban | 422 | $465,403 |
| OzempicSemaglutide | 336 | $388,799 |
| JardianceEmpagliflozin | 199 | $269,896 |
| XareltoRivaroxaban | 146 | $165,249 |
| RybelsusSemaglutide | 58 | $95,798 |
| TrulicityDulaglutide | 75 | $73,158 |
| BrilintaTicagrelor | 69 | $52,894 |
| Repatha SureclickEvolocumab | 28 | $35,094 |
| WegovySemaglutide | 23 | $31,444 |
| NexletolBempedoic Acid | 21 | $18,869 |
| Ambrisentan | 12 | $14,925 |
| VascepaIcosapent Ethyl | 14 | $12,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $10,412 | $560,285520 claims |
| Novo NordiskOzempic, Rybelsus, Wegovy | $31 | $516,041417 claims |
| NovartisEntresto | $107 | $477,524342 claims |
| PfizerEliquis | $143 | $465,403422 claims |
| Boehringer IngelheimJardiance | $73 | $269,896199 claims |
| Johnson & JohnsonXarelto | $753 | $165,249146 claims |
| Esperion Therapeutics, Inc.Nexletol | $201 | $18,86921 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $37 | $7,63519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Winchester
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Noah JonesFalls Church$238K
- Michael GenVirginia Beach$207K
- Jeremy BockLeesburg$202K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
- Jason FoerstRoanoke$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.